Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efarindodekin alfa
- Development stage
- Phase 2
- Lead developer
- Xilio Therapeutics
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Efarindodekin alfa is an **investigational, tumor-activated interleukin-12 (IL-12) immunotherapy** developed to stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic (“cold”) tumors into an inflamed, “hot” state. The drug employs a proprietary masking technology that restricts IL-12 activation to the tumor site, aiming to enhance efficacy while minimizing systemic toxicity. It is currently being investigated in Phase 1/2 clinical trials as a monotherapy in patients with advanced solid tumors. Early clinical data demonstrate promising anti-tumor activity, durable IFNγ signaling, and a favorable tolerability profile. The program originated with Xilio Therapeutics and is being advanced in partnership with Gilead Sciences[1][3][9].
- Other names
- efarindodekin alfaXTX301XTX-301XTX 301
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on efarindodekin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efarindodekin alfa.